Phase IV study coupling perfusion measures acquired from amyloid PET(Flutemetamol) with arterial spin labelling MR in advanced cognitively normal elderly individuals to establish the presence of fibrillar amyloid-beta (Aβ) pathology.
Phase of Trial: Phase IV
Latest Information Update: 08 Nov 2016
At a glance
- Drugs Flutemetamol-F-18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- 08 Nov 2016 New trial record